| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 04/09/2009 | US20090093444 Cathepsin Cysteine Protease Inhibitors |
| 04/09/2009 | US20090093433 SENSE mRNA THERAPY |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | DE102007046086A1 Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen Plant extract of low-THC cannabis in treating diseases |
| 04/09/2009 | CA2710406A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2701618A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation |
| 04/09/2009 | CA2701406A1 Benzoxazinone derivative |
| 04/09/2009 | CA2701404A1 Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti-inflammatory and the use thereof for the treatment of respiratory disorders |
| 04/09/2009 | CA2701118A1 Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases |
| 04/09/2009 | CA2699264A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2699260A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699255A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699114A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699113A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699109A1 Use of urocortin and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699107A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | CA2699104A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699078A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699074A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699067A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | CA2698690A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2698688A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2698687A1 Use of a peptide as a therapeutic agent |
| 04/08/2009 | EP2045245A1 Inreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof |
| 04/08/2009 | EP2045241A1 Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists |
| 04/08/2009 | EP2045234A1 New optical active phenylethanol amines and preparing method thereof |
| 04/08/2009 | EP2044957A1 Treatment agent for inflammatory bowel disease |
| 04/08/2009 | EP2044071A1 OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS |
| 04/08/2009 | EP2044070A1 Purine derivatives as a2a agonists |
| 04/08/2009 | EP2044056A1 Pyrimidine derivatives as alk-5 inhibitors |
| 04/08/2009 | EP2044025A1 Quinolinone derivatives and their pharmaceutical compositions |
| 04/08/2009 | EP2044023A1 Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
| 04/08/2009 | EP2043670A1 Fermented plant extracts, methods of production and uses |
| 04/08/2009 | EP1706114A4 Chemical inhibitors of soluble adenylyl cyclase (sac) |
| 04/08/2009 | EP1630160B1 The isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as the effective constituents |
| 04/08/2009 | EP1565475B1 Diazinopyrimidines and their use as protein kinase inhibitors |
| 04/08/2009 | EP1519749B1 Chemotactic factor inhibitor for inhibiting inflammatory reactions |
| 04/08/2009 | EP1461015B1 Compositions containing both sedative and non-sedative antihistamines |
| 04/08/2009 | EP1448566B3 Chemokine receptor antagonists and methods of use thereof |
| 04/08/2009 | EP1430023B1 Substituied urea retinoid agonists ii |
| 04/08/2009 | EP1415986B1 Spiro isobenzofuranes as neuropeptide y receptor antagonists |
| 04/08/2009 | EP1212299B1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 04/08/2009 | EP0931063B3 N-substituted indol-3-glyoxylamid with antiasthmatic, antiallergic and immunosuppressive/immunomodulating effect |
| 04/08/2009 | CN101405269A Substituted 1-amino-4-phenyl-dihydroisoquinolines, method for the production thereof, use thereof as a medicament, and medicaments containing them |
| 04/08/2009 | CN101405260A Amine derivatives |
| 04/08/2009 | CN101405001A Methods of inhibiting BTK and SYK protein kinases |
| 04/08/2009 | CN101404996A Composition containing lignan compound |
| 04/08/2009 | CN101404995A Lignane compound-containing oil-in-water emulsion and composition comprising the same |
| 04/08/2009 | CN101401937A Method of preparing coexpression PRRSV ORF5 and ORF6 double-gene nucleic acid vaccine |
| 04/08/2009 | CN101401936A Method of preparing coexpression PRRSV ORF5 and PCV2 ORF2 bivalent nucleic acid vaccine |
| 04/08/2009 | CN101401933A Uses of FGFR2IIIc cell lateral segment in preparing medicament for preventing and treating spontaneous pulmonary fibrosis |
| 04/08/2009 | CN101401880A Quality control method for Ditong rhinitis drop and mist |
| 04/08/2009 | CN101401876A Chinese medicinal composition for treating upper respiratory tract infection |
| 04/08/2009 | CN101401858A Preparation method for traditional Chinese medicine for treating frontal sinusitis |
| 04/08/2009 | CN101401841A Preparation method for medicine liqueur for treating bronchial asthma |
| 04/08/2009 | CN101401811A Budesonide R capsule type inhalation dust cloud agent and preparation method thereof |
| 04/08/2009 | CN101401807A Uses of selective JAK3 restrainer VI in antiviral mediated acute lung damnification |
| 04/08/2009 | CN100475262C Liver-soothing and qi-dispersing medicine for preventing and treating SARS and viral hepatitis complication |
| 04/08/2009 | CN100475258C Antasthmatic |
| 04/08/2009 | CN100475242C Chinese medicinal preparation for treating respiration system virus infection disease and preparation method thereof |
| 04/08/2009 | CN100475241C Yankening medicine preparation and preparing method thereof |
| 04/08/2009 | CN100475223C Medicament box used for treating acute anhelation syndrome |
| 04/08/2009 | CN100475195C Micro-pills of Niuhuang Shangqing Wan Contg. calculus Bovis, and prepn. method thereof |
| 04/07/2009 | US7514571 Bicyclo derivative |
| 04/07/2009 | US7514564 Substituted amine derivatives and methods of use |
| 04/07/2009 | US7514535 Chimeric immunogens |
| 04/07/2009 | US7514469 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse |
| 04/07/2009 | US7514456 Nicotinamide derivatives useful as p38 inhibitors |
| 04/07/2009 | US7514449 inhibitor of activated blood coagulation factor X; N-(5-chloropyridin-2-yl)-3- {[(trans-4-pyrrolidin-1 -ylcyclohexyl)carbonyl]aznino}furo[3,2-c]pyridine-2-carboxaxnide; disorders caused by thrombi and emboli in a mammal; decreased toxicity, and causes few side effects |
| 04/07/2009 | US7514422 To treat obesity, schizophrenia, anxiety, depression, alcoholism; using 3-benoazepine compounds like 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin); serotonin 2c receptor agonists |
| 04/07/2009 | US7514239 Nucleotide sequences coding polypeptide for use in the treatment of preferential glandular disorders |
| 04/07/2009 | US7514225 detecting drugs that inhibits the binding of macrophage migration inhibitory factor (MIF) to an antimacrophage migration inhibitor factor monoclonal or polyclonal antibody; drug screening |
| 04/07/2009 | US7514105 Bioavailability/bioefficacy enhancing activity of Cuminum cyminum and extracts and fractions thereof |
| 04/07/2009 | CA2493633C Kinase inhibitors |
| 04/07/2009 | CA2463294C Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/07/2009 | CA2458684C Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
| 04/07/2009 | CA2415890C N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 04/07/2009 | CA2372384C Anti-inflammatory bioactive glass particulates |
| 04/07/2009 | CA2362833C Phenylalaninol derivatives |
| 04/07/2009 | CA2361998C Aromatic heterocyclic compounds as anti-inflammatory agents |
| 04/07/2009 | CA2352503C Il-5 inhibiting 6-azauracil derivatives |
| 04/07/2009 | CA2339253C Inhibitors of p38 |
| 04/07/2009 | CA2237157C Cyclopeptolide inhibitors of adhesion molecules |
| 04/07/2009 | CA2210871C Human dnase i variants |
| 04/02/2009 | WO2009042806A1 Polo-like kinase inhibitors |
| 04/02/2009 | WO2009042711A1 Polo-like kinase inhibitors |
| 04/02/2009 | WO2009042544A1 Quinone derivatives, pharmaceutical compositions, and uses thereof |
| 04/02/2009 | WO2009042542A1 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
| 04/02/2009 | WO2009042395A1 Compositions comprising quinolone and methods for treating or controlling infections |
| 04/02/2009 | WO2009042139A1 2-s-benzyl substituted pyrimidines as crth2 antagonists |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041026A1 Cxcl10 production inhibitor |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040087A2 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |